Stocktoria
Jaguar Health, Inc. JAGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-05-13
Jaguar Health, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M |
| R&D expense | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M |
| Operating income | -$45.9M | -$30.8M | -$34.3M | -$34.4M | -$40.7M |
| Interest expense | $67,000 | $231,000 | $6.4M | $12.7M | $8.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$53.6M | -$38.5M | -$41.3M | -$47.5M | — |
| EPS (diluted) | $-22.97 | $-130.69 | $-2678.17 | $-36.18 | $-88.22 |
| Operating cash flow | -$23.7M | -$29.4M | -$33.2M | -$33.1M | -$35.0M |
| Free cash flow | — | -$29.4M | — | -$33.2M | -$35.0M |
| Cash & equivalents | $968,000 | $8.0M | $6.5M | $5.5M | $17.1M |
| Inventory | $8.6M | $10.3M | $9.2M | $7.0M | $4.9M |
| Total assets | $38.3M | $53.4M | $50.8M | $47.5M | $53.3M |
| Total liabilities | $57.0M | $44.4M | $45.9M | $48.8M | $41.4M |
| Shareholders' equity | -$18.7M | $6.5M | $4.9M | -$1.4M | $11.9M |
Source: SEC EDGAR filings · CIK 0001585608 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.